Managing ischemic risk after PCI in diabetic patients: advances in antiplatelet strategies

Zavkiddinovich, Orziev Daler and Khatamovich, Akbar Abdullaev (2025) Managing ischemic risk after PCI in diabetic patients: advances in antiplatelet strategies. World Journal of Biology Pharmacy and Health Sciences, 22 (2). pp. 164-170. ISSN 2582-5542

Background: Type 2 diabetes mellitus (T2DM) significantly increases the risk of adverse cardiovascular outcomes, particularly following percutaneous coronary intervention (PCI). Diabetic patients experience accelerated atherosclerosis, heightened platelet reactivity, and endothelial dysfunction, contributing to an increased risk of recurrent ischemic events, including myocardial infarction and stent thrombosis. Optimal antiplatelet therapy in this high-risk group remains a clinical challenge due to the need to balance thrombotic protection with bleeding risk. Objective: This review aims to summarize current antiplatelet strategies and highlight recent advances in managing ischemic risk in diabetic patients after PCI. Emphasis is placed on drug selection, therapy duration, individualized approaches, and emerging evidence from clinical trials and precision medicine. Methods: A narrative review of key randomized controlled trials, meta-analyses, guideline documents (ESC, ACC/AHA), and observational studies published between 2009 and 2024 was conducted using PubMed and clinical trial registries. Studies focusing on antiplatelet therapy in patients with T2DM undergoing PCI were prioritized. Key Findings: Ticagrelor and prasugrel offer superior platelet inhibition and ischemic protection compared to clopidogrel in diabetic patients, though at the cost of increased bleeding. Risk stratification tools such as the DAPT and PRECISE-DAPT scores assist in tailoring therapy duration and intensity. Recent trials (e.g., THEMIS-PCI, PEGASUS-TIMI 54, TWILIGHT) support individualized strategies including de-escalation and monotherapy in select patients. Innovations such as platelet function testing, CYP2C19 genotyping, dual pathway inhibition, and artificial intelligence-driven risk prediction are paving the way for precision-guided antiplatelet therapy. Conclusion: Management of ischemic risk in diabetic patients post-PCI should be individualized and evidence-based. Future research should focus on validating precision tools, refining risk models, and identifying optimal long-term strategies that balance ischemic protection with safety.